SCIB Granted RM16.8 Million Contract for School Construction
KUCHING, MALAYSIA, Mar 28, 2023 – (ACN Newswire) – Civil engineering specialist Sarawak Consolidated Industries…
Month: March 2023
Tech Week Singapore Reveals Brand-New Summit for Data and AI Leaders
SINGAPORE, Mar 28, 2023 – (ACN Newswire) – Tech Week Singapore, an award-winning event by…
RepRisk Launches ESG Risk Data on Snowflake Marketplace
Joint customers can identify and assess material ESG risks to inform financial decision-making with RepRisk…
Asahi Kasei and NEC establish analysis platform utilizing secure computation technology for secure data collaboration between companies
TOKYO, Mar 28, 2023 – (JCN Newswire) – Asahi Kasei Corp. (Asahi Kasei) and NEC…
Fujitsu launches new cloud-based platform for healthcare sector in Japan, promoting personalized healthcare and drug development
TOKYO, Mar 28, 2023 – (JCN Newswire) – Fujitsu today announced the launch of a…
Mohamed Al Banna Joins Rare FND as an Advisor and Co-Founder
DUBAI, UAE, Mar 28, 2023 – (ACN Newswire) – Rare FND, the Blockchain based fundraising…
Boomi Opens New Office in Bengaluru With Aim To Innovate the Future of Enterprise Automation
Boomi, a category-leading, global software as a service (SaaS) company, plans to double its current…
Axiom Exhibiting at Outsourcing in Clinical Trials Southeast 2023
TORONTO, March 27, 2023 (GLOBE NEWSWIRE) — Axiom Real-Time Metrics (“Axiom”), a premier provider of…
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial
Results published in The New England Journal of Medicine and presented simultaneously at ESMO Virtual…
Driivz Names Benjamin Low as Vice President for APAC
Appointment signals expansion of Driivz EV charging and energy management software in Asia Pacific markets…
BREATHE! Convention Launches Unprecedented NFT Ticketing Function for Attendees Using NFT-TiX Marketplace
LAS VEGAS, NV, March 28, 2023, (ACN Newswire) – BREATHE! Convention, the highly anticipated Web3…
CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment
Recent CAN008 Phase 1 Follow-Up Data Showed 67% 5-Year Overall Survival in High-Dose Cohort, Reported…
CORRECTING and REPLACING World’s Leading Customer Data Platform Adobe Real-Time CDP Debuts Industry-First Innovations
Adobe Real-Time Customer Data Platform – used by leading brands including Chipotle, Major League Baseball,…
Berry Global Announces Consideration for and Upsizing of Tender Offer for 0.95% First Priority Senior Secured Notes due 2024
EVANSVILLE, Ind.–(BUSINESS WIRE)–Berry Global Group, Inc. (NYSE: BERY) (“Berry”), a leading supplier of packaging solutions…
Berry Global Announces Pricing of Offering of First Priority Senior Secured Notes
EVANSVILLE, Ind.–(BUSINESS WIRE)–Berry Global Group, Inc. (NYSE: BERY) (“Berry”), a leading supplier of packaging solutions…
Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
WILMETTE, Ill., March 27, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
WILMETTE, Ill., March 27, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Tilray Brands, Inc. to Announce Third Quarter Fiscal 2023 Financial Results on April 10, 2023
NEW YORK and LEAMINGTON, Ontario, March 27, 2023 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”…
Tilray Brands, Inc. to Announce Third Quarter Fiscal 2023 Financial Results on April 10, 2023
NEW YORK and LEAMINGTON, Ontario, March 27, 2023 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”…
CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
– Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3)…